IRRAS Gestion

Gestion contrôle des critères 3/4

We currently do not have sufficient information about the CEO.

Informations clés

Will Martin

Directeur général

SEK 6.7m

Rémunération totale

Pourcentage du salaire du PDG	61.2%
Durée du mandat du directeur général	6yrs
Propriété du PDG	0.02%
Durée moyenne d'occupation des postes de direction	4.3yrs
Durée moyenne du mandat des membres du conseil d'administration	7yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Will Martin a-t-elle évolué par rapport aux bénéfices de IRRAS?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2023	n/a	n/a	-SEK 196m
Mar 31 2023	n/a	n/a	-SEK 193m
Dec 31 2022	SEK 7m	SEK 4m	-SEK 167m
Sep 30 2022	n/a	n/a	-SEK 164m
Jun 30 2022	n/a	n/a	-SEK 141m
Mar 31 2022	n/a	n/a	-SEK 131m
Dec 31 2021	SEK 3m	SEK 2m	-SEK 136m

Rémunération vs marché: Will's total compensation ($USD640.30K) is about average for companies of similar size in the German market ($USD631.03K).

Rémunération et revenus: Will's compensation has increased whilst the company is unprofitable.

PDG

Will Martin (48 yo)

6yrs

Titularisation

SEK 6,679,000

Compensation

Mr. Will Martin has been the Chief Executive Officer at IRRAS AB (publ) since July 01, 2021. He had been the Chief Commercial Officer and a member of the executive management team of IRRAS AB (publ) (IRRAS...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Will Martin	President & CEO	6yrs	SEK 6.68m	0.018% € 29.6k
Kleanthis Xanthopoulos	Executive Director	2.5yrs	SEK 530.00k	1.15% € 1.9m
Griffen Stapp	Interim Chief Financial Officer	2.4yrs	pas de données	pas de données
Kellie Fontes	Vice President of Human Capital	5.9yrs	pas de données	0.083% € 139.5k
Niloufa Insanally	Head of Regulatory Affairs	4.3yrs	pas de données	pas de données

4.3yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Gestion expérimentée: 4Z7's management team is considered experienced (4.3 years average tenure).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Kleanthis Xanthopoulos	Executive Director	9yrs	SEK 530.00k	1.15% € 1.9m
Marios Fotiadis	Chairman of the Board	12yrs	SEK 540.00k	20.2% € 33.9m
Anita Tollstadius	Independent Director	7yrs	SEK 380.00k	0.010% € 17.0k
Christos Panotopoulos	Special Advisor & Member of Clinical Advisory Board	5.6yrs	pas de données	pas de données
Catherine Gilmore-Lawless	Independent Director	4.7yrs	SEK 471.00k	pas de données

7.0yrs

Durée moyenne de l'emploi

64yo

Âge moyen

Conseil d'administration expérimenté: 4Z7's board of directors are considered experienced (7 years average tenure).

IRRAS Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Insufficient new directors

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022)

Insufficient new directors

Insufficient new directors

Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021)

IRRAS AB (publ) Announces That the Publication of the First Comparative Study

IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024

Insufficient new directors

IRRAS Receives US FDA 510(K) Clearance for Its Next Generation IRRAflow Control Unit

Insufficient new directors

IRRAS AB (publ) SHARE AK to Be Deleted from OTC Equity

IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023

Insufficient new directors

IRRAS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 214.599618 million.

Irras Announces First Patient Treatments At Mount Sinai Health System in New York as Part of the Dive Study

Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021)

IRRAS AB Provides Revenue Guidance for the Year 2022

Insufficient new directors

IRRAS AB (publ) Announces First Global Patient Treatment with Next-Generation IRRAflow® System

IRRAS AB (publ) Launches Next-Generation of the IRRAflow System in the United States

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

IRRAS AB (publ) to Report Q2, 2022 Results on Jul 22, 2022

IRRAS Announces Presentation of the Dataset to Date to Document Clinical Outcomes Using Its IRRAflow system

IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow's Efficacy to Traditional Passive Drainage

Third quarter 2021 earnings released: kr0.34 loss per share (vs kr0.47 loss in 3Q 2020)

IRRAS AB (publ) Demonstrates Ability to Treat Pyogenic Ventriculitis Through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.55 loss in 2Q 2020)

IRRAS AB Receives Extension of Its MDSAP Certification and Scope Expansion of MDSAP & ISO 13485:2016 Certifications

IRRAS AB Announces Publication of A Case Report from Buffalo General Medical Center, Highlights Clinical Superiority of IRRAflow Treatment Versus Traditional Drainage

First quarter 2021 earnings released: kr0.58 loss per share (vs kr1.19 loss in 1Q 2020)

Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations

New 90-day low: €0.62

Full year 2020 earnings released: kr24.64 loss per share (vs kr5.61 loss in FY 2019)

Revenue misses expectations

Irras AB Announces an Exclusive Distribution Agreement with Medical Innovation Solutions

IRRAS AB Announces Exclusive Distribution Agreement with Anade SA

New 90-day high: €0.81

IRRAS AB Announces an Exclusive Distribution Agreement with KM Innovations BV

IRRAS AB Announces Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products

Revenue misses expectations

Third quarter 2020 earnings released: kr0.47 loss per share

New 90-day high: €0.66

First half earnings released

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen